LAVA Therapeutics N.V. (NASDAQ:LVTX) Receives $2.69 Consensus Target Price from Brokerages

Shares of LAVA Therapeutics N.V. (NASDAQ:LVTX) have earned a consensus rating of “Reduce” from the four analysts that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and three have assigned a hold recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $1.37.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of LAVA Therapeutics in a research note on Wednesday, October 8th.

LAVA Therapeutics Stock Performance

NASDAQ:LVTX opened at $1.74 on Monday. LAVA Therapeutics has a 52 week low of $0.85 and a 52 week high of $2.00. The firm has a 50-day moving average price of $1.65 and a two-hundred day moving average price of $1.52. The firm has a market cap of $45.77 million, a price-to-earnings ratio of -2.02 and a beta of 0.50.

LAVA Therapeutics (NASDAQ:LVTX) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). As a group, sell-side analysts forecast that LAVA Therapeutics will post -1.13 earnings per share for the current year.

Insider Transactions at LAVA Therapeutics

In other news, major shareholder Gilde Healthcare Cooperatieve sold 1,181,131 shares of the stock in a transaction that occurred on Friday, October 17th. The shares were sold at an average price of $1.47, for a total transaction of $1,736,262.57. Following the completion of the transaction, the insider directly owned 2,947,781 shares of the company’s stock, valued at $4,333,238.07. This represents a 28.61% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Versant Venture Capital Vi, L. sold 2,370,533 shares of LAVA Therapeutics stock in a transaction that occurred on Friday, September 19th. The stock was sold at an average price of $1.40, for a total transaction of $3,318,746.20. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 6,861,226 shares of company stock worth $9,944,164. Corporate insiders own 9.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Shay Capital LLC purchased a new stake in shares of LAVA Therapeutics during the 3rd quarter valued at approximately $3,976,000. Rangeley Capital LLC purchased a new position in LAVA Therapeutics in the 2nd quarter valued at approximately $36,000. XTX Topco Ltd bought a new stake in LAVA Therapeutics during the 1st quarter valued at $31,000. Lepercq De Neuflize Asset Management LLC purchased a new stake in shares of LAVA Therapeutics during the first quarter worth $29,000. Finally, BML Capital Management LLC boosted its holdings in shares of LAVA Therapeutics by 0.5% in the second quarter. BML Capital Management LLC now owns 1,970,610 shares of the company’s stock worth $2,601,000 after acquiring an additional 10,000 shares during the period.

LAVA Therapeutics Company Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.